The FDA recently approved three new drugs for the treatment of type 2 diabetes, all featuring the new SGLT-2 inhibitor, ertugliflozin. The first, Steglatro, is ertugliflozin available in 5-mg and 15-mg tablets, approved for adults with type 2 as an adjunct to diet and exercise to improve glycemic control. The second, Steglujan, is a tablet combining ertugliflozin and sitagliptin (a DPP-4 inhibitor), and is also indicated to improve glycemic control in type 2. Finally, Segluromet tablets combine ertugliflozin & metformin hydrochloride, and are recommended as an adjunct to diet and exercise to improve glycemic control for adults with type 2 whose diabetes is  not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. Read more